Case Report of Mabwell’s Nectin-4 targeting ADC (9MW2821) in Cervical Cancer Published in The New England Journal of Medicine
SHANGHAI, April 21, 2026 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industrial chain, announced that...
Read moreDetails